Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.
A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.
Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.
This year’s Rheumatic Disease Awareness Month encourages rheumatology professionals to collaborate with patients on physical activity routines that benefit their health.